Argus II retinal prosthesis system: a review of patient selection criteria, surgical considerations, and post-operative outcomes [PDF]
Clinical Ophthalmology, 2018 Avni P Finn, Dilraj S Grewal, Lejla Vajzovic Department of Ophthalmology, Duke University Eye Center, Durham, NC, USA Abstract: Retinitis pigmentosa (RP) is a group of heterogeneous inherited retinal degenerative disorders characterized by progressive ...
Finn AP, Grewal DS, Vajzovic L
doaj +3 more sources
Argus II retinal prosthesis malrotation and repositioning with intraoperative optical coherence tomography in a posterior staphyloma [PDF]
Clinical Ophthalmology, 2015 Michael I Seider, Paul Hahn Duke University Eye Center, Durham, NC, USA Introduction: The Argus II retinal prosthesis may improve visual function in patients with severe vision loss from retinitis pigmentosa.
Seider MI, Hahn P
doaj +3 more sources
Visual BOLD Response in Late Blind Subjects with Argus II Retinal Prosthesis. [PDF]
PLoS Biology, 2016 Retinal prosthesis technologies require that the visual system downstream of the retinal circuitry be capable of transmitting and elaborating visual signals.
E Castaldi +5 more
doaj +7 more sources
The cost-effectiveness of the Argus II retinal prosthesis in Retinitis Pigmentosa patients. [PDF]
BMC Ophthalmol, 2014 BMC ophthalmology 14, 49 (2014).
Vaidya A +7 more
europepmc +20 more sources
The Functional Performance of the Argus II Retinal Prosthesis [PDF]
Expert Review of Medical Devices, 2014 Visual prostheses are devices to treat profound vision loss by stimulating nerve cells anywhere along the visual pathway, typically with electrical pulses. The Argus II implant, developed by Second Sight Medical Products (SSMP, Sylmar, CA, USA), targets the retina and features 60 electrodes that electrically stimulate the surviving retinal neurons.
Gislin Dagnelie +1 more
exaly +5 more sources
Beyoglu Eye Journal, 2017 The Argus II Retinal Prosthesis System (Second Sight Medical Products, Inc., Sylmar, CA, USA) is the first US Food and Drug Administration-approved retinal implant.
İrfan Perente +2 more
doaj +3 more sources
Long-term visual outcomes and rehabilitation in Usher syndrome type II after retinal implant Argus II [PDF]
BMC Ophthalmology, 2018 Background The aim of this article is to describe visual outcomes and posterior rehabilitation of the first Usher syndrome type II (USH2) patient receiving an Argus II (®) prosthesis.
Jeroni Nadal, María Iglesias
doaj +2 more sources
Endoscope-Assisted and Controlled Argus II Epiretinal Prosthesis Implantation in Late-Stage Retinitis Pigmentosa: A Report of 2 Cases [PDF]
Case Reports in Ophthalmology, 2016 Several different approaches for restoring sight in subjects who are blind due to outer retinal degeneration are currently under investigation, including stem cell therapy, gene therapy, and visual prostheses.
Emin Özmert, Sibel Demirel
doaj +2 more sources
A Genome-Wide Association Study Identifies Candidate SNPs and Genes Associated with Body Weight in the Northern Snakehead (Channa argus) Using a 50K SNP Array [PDF]
AnimalsBody weight is the principal economic trait in snakehead aquaculture, yet the genetic architecture of growth in the northern snakehead (Channa argus) remains largely unexplored.
Haiyang Liu +11 more
doaj +2 more sources
Brain-computer interface commercialization [PDF]
Journal of NeuroEngineering and RehabilitationBackground Brain-computer interfaces (BCIs) have emerged as powerful tools to restore neurological function lost due to injury or degeneration. Despite scientific advancements, successful commercialization remains challenging.
Jackson Powell, Anson Zhou
doaj +2 more sources